J Korean Cancer Assoc.  2000 Jun;32(3):476-486.

Expression of MDM-2 and p53 Proteins in Gastric Adendegrees Carcinoma and Its Relationship with Clinicopathologic Factors

• Yang JW
• Kim HJ
• Lee TJ
• Park ES
• Yoo JH

Abstract

PURPOSE: MDM-2 is an oncoprotein that inhibits p53 tumor-suppressor protein. These abnor malities have a role in tumorigenesis through inactivation of p53 function. To determine the clini copathological and prognostic value of MDM2 abnormalities in gastric adendegrees Carcinoma, MDM-2& p53 protein expression were analysed in surgically resected materials of gastric adendegrees Carcinoma.
MATERIALS AND METHODS
Fifty cases which had got follow-up after surgical resection were immunohistdegrees Chemically studied with p53 and MDM-2 antibodies. We defined variable clinico pathologic factors for expression of p53 and MDM-2 protein and analysed their relationships.
RESULTS
Immunohistdegrees Chemical stain revealed expression of MDM-2 protein as a 52.0% (26/50) and p53 protein 20.0% (10/50), respectively. But their expressions were not assdegrees Ciated with clinicopathological factors such as T-factor, N-factor, stage, histology and differentiation. Overall, p53-negative patients seemed to have a better prognosis regardless of MDM-2 protein status (P= 0.057). MDM-2 protein status was considered to have no play as a prognostic factor.
CONCLUSION
In the gastric adendegrees Carcinoma, p53 protein expression seemed to have a inverse relationship with clinical outcomes but MDM-2 protein expression, which was observed more frequently than those of p53, seemed not to be prognostic indicator.

Keyword

p53 protein; Murine double minute-2 protein; Stomach neoplasm

MeSH Terms

Antibodies
Carcinogenesis
Follow-Up Studies
Humans
Prognosis
Proto-Oncogene Proteins c-mdm2
Stomach Neoplasms
Antibodies
Proto-Oncogene Proteins c-mdm2